Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.40 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.40 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3582094 | 0.78 | PI4KA (0.38) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL9970894 | 0.71 | ALDH1A1 (0.33) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL16780344 | 0.70 | ALDH1A1 (0.36) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL9970895 | 0.67 | LMNA (0.41) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL8228313 | 0.66 | DYRK1A (0.54) | ALDH1A1MAPT | |
| SCHEMBL8227604 | 0.65 | DYRK1A (0.41) | ALDH1A1POLBSMN1; SMN2GLAGAA | |
| SCHEMBL12311290 | 0.65 | CYP17A1 (0.36) | — | |
| SCHEMBL29674849 | 0.64 | — | — | |
| SCHEMBL8234099 | 0.63 | DYRK1A (0.35) | ALDH1A1POLBSMN1; SMN2GLAGAA | |
| SCHEMBL970593 | 0.62 | ALDH1A1 (0.36) | ALDH1A1POLBSMN1; SMN2GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202876-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-06-19 | — | — | US | disclosed |
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | FYN, ABL2, LCK | PI4KA 589/4885PI4K2B 366/4885PI4K2A 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.